Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in Relapsed Small Cell Lung Cancer
NCT00086827Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2004
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 4 years. Started May 2004; status: completed.
02
Drugs
romidepsin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00086827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086827.